Search
forLearn
5 / 801 resultslearn heptyl glucoside
learn capilia longa
learn Salicylic acid
learn Lipodermal base
Research
5 / 1000+ results
research The regeneration of caudal epidermal specializations inLygodactylus picturatus keniensis (gekkonidae, Lacertilia)
Lizards can regrow their tail scales with the same structure, distribution, and gender-specific features as the original ones, and this unique ability is not seen in adult mammals.
research A pilot study of ICG laser therapy of acne vulgaris: Photodynamic and photothermolysis treatment
ICG-enhanced NIR laser therapy may be a promising acne treatment with improvement and no side effects.
research Regenerating the skin: a task for the heterogeneous stem cell pool and surrounding niche
Different types of stem cells and their environments are key to skin repair and maintenance.
research Morpho-Regulation of Ectodermal Organs
Modulating BMP activity changes the number, size, shape, and type of ectodermal organs.
research Sensitive skin
Sensitive skin often causes discomfort, affects many people, especially women and older adults, and should be managed with careful product selection.
Community Join
5 / 1000+ resultscommunity PELAGE PHASE 2 TRIALS FOR PP405 - Volunteers Needed
PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
community It looks like Pelage are giving hints that PP405 is a game changer
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
community Approve PP405 quickly you coward
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 28th march
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
community Pelage are starting phase 3 for PP405 towards the end of 2026
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.